Innovent Biologics, Inc. (IVBXF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Suzhou, China. Der aktuelle CEO ist De-Chao Yu.
IVBXF hat IPO-Datum 2019-09-04, 5,659 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $18.15B.
Innovent Biologics, Inc. is a China-based biopharmaceutical company founded in 2011 and headquartered in Suzhou that specializes in discovering, developing, and manufacturing antibody-based therapeutics for oncology, ophthalmology, immunology, and metabolic diseases. The company's commercial pipeline includes Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody approved for various cancers, along with several other marketed products such as Byvasda, Halpryza, Pemazyre, and Olverembatinib targeting hematologic and solid tumors. Beyond its marketed products, Innovent is advancing a robust clinical development program encompassing biosimilars, bispecific antibodies, CAR-T cell therapies, and immunotherapies, including candidates like IBI-302 for ocular diseases and IBI-326 for multiple myeloma. The company has established strategic collaborations with leading global pharmaceutical partners including Roche, Eli Lilly, and others to enhance its drug development capabilities. Additionally, Innovent provides pharmaceutical distribution, consultation, and research and development services to support its position as a comprehensive biopharmaceutical enterprise.
